Post-infectious irritable bowel syndrome.

##plugins.themes.academic_pro.article.sidebar##

Published Mar 30, 2012
Download
pdf
Vol. 90 No. 3 (2012): Issue Mar 2012

##plugins.themes.academic_pro.article.main##

Meriem Serghini
Sami Karoui
Jalel Boubaker
Azza Filali

Abstract

Background: Post-infectious irritable bowel syndrome (PI-IBS) is a disorder wherein symptoms of IBS begin after an episode of acute gastroenteritis.
Aims: To determine epidemiology, clinical features and prognosis of PI-IBS and to precise its physiopathology and treatment.
Methods: Literature review.
Results: Published studies have reported an incidence of PI-IBS ranging from 4 to 32 % with a mean of 10 %. Bacterial infections are the most responsible agents. Risk factors for PI-IBS include patient’s demographics, psychological disorders and the severity of enteric illness. The most common symptoms are those of diarrheapredominant IBS. The mechanisms underlying PI-IBS include especially changes in intestinal permeability and persistent mucosal inflammatory process. In fact, there is increase in lymphocytic, mast and enterochromaffin cells in the gut mucosa. Furthermore, increased inflammatory cytokines have been demonstrated. Treatment of PIIBS is similar to that idiopathic IBS.
Conclusion: PI-IBS is a novel clinic entity that suggests a novel approaches to IBS.

Keywords:

Irritable bowel syndrome, infections, gastroenteritis, physiopathology.

##plugins.themes.academic_pro.article.details##

References

  1. Horowitz BJ, Fisher RS. The irritable bowel syndrome. N Engl J Med 2001;344:1846-50
  2. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006;130: 1377-90
  3. DuPont AW. Post-infectious irritable bowel syndrome. Current Gastroenterol Reports 2007;9:378-84
  4. Stewart GT. Post-dysenteric colitis. Br Med J 1950; 18: 405-9.
  5. McKendrick MW, Read NW. Irritable bowel syndrome-post Salmonella infection. J Infect 1994; 39: 1-3.
  6. Neal KR, Hebden J, Spiller J. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome : postal survey of patients. Br Med J 1997; 314: 779-82.
  7. Gwee KA, Leong YL, Graham C. The role of psychological and biological factors in postinfective gut dysfunction. Gut 1999;44:400-6
  8. Gwee KA, Graham JC, McKendrick MW. Psychometric scores and persistence of irritable bowel after infectious diarrhea. Lancet 1996; 347: 150-3.
  9. Garcia Rodriguez LA, Ruigomez A. Increased risk of irritable bowel syndrome after bacterial gastroenteritis. Br Med J 1999; 318: 565-6.
  10. Parry SD, Stanfield R, Jelley D. Does bacterial gastroenteritis predispose people to functional gastrointestinal disorders? A prospective, community-based, case-control study. Am J Gastroenterol 2003; 98: 1970-5.
  11. Marshall JK, Thabane M, Garg AX. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology 2006; 131:445-50.
  12. Marshall JK, Thabane M, Garg AX, Clark WF, Collins SM. Prognosis in post-infectious irritable bowel syndrome: a six year follow up after the Walkerton waterborne outbreak of gastroenteritis. Gastroenterology 2007; 132:A66.
  13. Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 2003; 125: 1651-9.
  14. Halvorson HA, Schlett CD, Riddle MS. Postinfectious irritable bowel syndrome: a meta-analysis. Am J Gastroenterol 2006;101:1894-9
  15. Thabane M, Kottachchi DT, Marshall JK. Systematic review and meta-analysis: the incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2007;26:535- 44
  16. Piche T, Vanbiervliet G, Pipeau FG, Dainese R. Low risk of irritable bowel syndrome after Clostridium difficile infection. Can J Gastroenterol 2007 ;21 :727-31
  17. Hanevik K, Dizdar V, Langeland N, Hausken T. Development of functional gastrointestinal disorders after Giardia lamblia infection. BMC Gastroenterology 2009;9:27-31
  18. Marshall JK, Thabane M, Borgaonkar MR, James C. Postinfectious irritable bowel syndrome after a food-borne outbreak of acute gastroenteritis attributed to a viral pathogen. Clin Gastroenterol Hepatol 2007;5:457-60
  19. Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 2003; 125: 1651-9.
  20. Ji S, Park H, Lee D, Song YK, Choi JP, Lee SI. Post-infectious irritable bowel syndrome in patients with Shigella infection. J Gastroenterol Hepatol 2005;20:381-6
  21. Arrieta MC, Bistritz L, Meddings JB. Alterations in intestinal permeability. Gut 2006;55:1512-20
  22. Spiller RC, Jenkins D, Thornley JP. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in postdysenteric irritable bowel syndrome. Gut 2000;47:804-11.
  23. Marshall JK, Thabane M, Garg AX, Clark W, Meddings J, Collins SM. Intestinal permeability in patients with irritable bowel syndrome after waterborne outbreak of acute gastroenteritis in Walkerton, Ontario. Aliment Pharmacol Ther 2004; 20: 1317-22.
  24. Dunlop SP, Hebden J, Campbell E. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol 2006; 101:1288-94.
  25. Piche T, Collins SM, Rampal P. Role of enteric infections and inflammation in functional bowel disorders. Gastroenterol Clin Biol 2002; 26: 624-9.
  26. Piche T, Barbara G, Aubert P. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 2009; 58:196-201.
  27. Zhou Q, Zhang B, Verne GN. Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome. Pain 2009; 146:41-6.
  28. Dunlop SP, Jenkins D, Spiller RC. Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am J Gastroenterol 2003; 98:1578-83.
  29. Wang LH, Fang XC, Pan GZ. Bacillary dysentery as causative factor of irritable bowel syndrome and its pathogenesis. Gut 2004; 53:1096-101.
  30. Lee KJ, Kim YB, Kim JH, Know HC, Kim DK, Cho SW. The alteration of enterchromaffine cell, mast cell and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors. J Gastroenterol Hepatol 2008;23:1689-94
  31. Barbara G, Stanghellini V, De Giorgio R, Cremon C, Di Nardo G. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004;126:693-702
  32. Gabay C, Lamacchia C, Palmer G. IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol. 2010; 6:232-41.
  33. Gwee KA, Collin SM, Read NW. Increased rectal mucosal expression of interleukin 1‚ in recently acquired post-infectious irritable bowel syndrome. Gut 2003; 52:523-6.
  34. Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995;109:40-52.
  35. Barbara G, Wang B, Stanghellini V, De Giorgio R, Cremon C, Di Nardo G. Mast cell-dependent excitation of visceral nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 2007; 132:26-37.
  36. Jee SR, Morales W, Low K. ICC density predicts bacterial overgrowth in a rat model of post-infectious IBS. World J Gastroenterol 2010;16: 3680-6.
  37. Dunlop SP, Coleman NS, Blackshaw E, Perkins AC, Singh G, Marsden CA. abnormalities of 5-hydrxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005;3:349-57.
  38. Barman M, Unold D, Shifley K, et al. Enteric salmonellosis disrupts the microbial ecology of the murine gastrointestinal tract. Infect Immun 2008; 76: 907-15.
  39. Pimentel M, Chatterjee S, Chang C, et al. A new rat model links two contemporary theories in irritable bowel syndrome. Dig Dis Sci 2007; 53:982-9.
  40. Collins SM, Denou E, Verdu EF, Bercik P. The putative role of the intestinal microbiota in the irritable bowel syndrome. Dig Liver Dis 2009; 41:850-3.
  41. Bijkerk CJ, Muris JWM, knottnerus JA, Hoes AW, De Wit NJ. Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004; 19: 245-51.
  42. Park MI, Camilleri M. Is there a role of food allergy in irritable bowel syndrome and functional dyspepsia? A systematic review. Neurogastroenterol Motil 2006 ; 18 : 595-607.
  43. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001;15:355-61
  44. Wittmann T, Paradowski L, Ducrotte P, Bueno L, Andro Delestrain MC. Clinical trial: efficacy of alverine citrate â„ simeticone combination on abdominal pain â„ discomfort in irritable bowel syndrome - a randomized, double-blind, placebocontrolled study. Aliment Pharmacol Ther 2010; 31: 615-24.
  45. Chassamy O, Bonaz B, Bruley des Varannes S, Bueno L, Cargill, G, Coffin B. Acute exacerbation of pain in irritable bowel syndrome: efficacy of phloroglucinol/trimethyl-phloroglucinol. A randomized double blind, placebo controlled study. Aliment Pharmacol Ther 2007; 25:1115-23.
  46. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis. World J Gastroenterol 2009 ;15:1548-53.
  47. Cremonini F, Delgado-Aros S, Camilleri M. Efficacy of alosertron in irritable bowel sndrome: a meta-analysis of randomised controlled trials. Neurogastroenterol Motil 2003;15:79-86
  48. Dizdar V, Gilja OH, Hausken T. Increased visceral sensitivity in Giardia-induced postinfectious irritable bowel syndrome and functional dyspepsia. Effect of the 5HT3-antagonist ondansetron. Neurogastroenterol Motil 2007; 19:977-82.
  49. Aragon G, Graham DB, Borum M, Doman DB. Probiotic therapy for irritable bowel syndrome. Gastroenterol Hepatol 2010 ;6:39- 44.
  50. Resta-Lenert S, Barett KE. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escheria coli (EIEC). Gut 2003; 52:988-97.
  51. Frissora CL, Cash BD. Review article: the role of antibiotics vs. conventional pharmacotherapy in treating symptoms of irritable bowel syndrome. Aliment Pharmacol Ther 2007; 25:1271-81.
  52. Dunlop SP, Jenkins D, Neal KR. Randomized, double-blind, placebo-controlled trail of prednisolone in post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2003; 18:77- 84.
  53. Barbara G, Stanghellini V, Cremon C. Aminosalicylates and other anti-inflammatory compounds for irritable bowel syndrome. Dig Dis 2009;27 (Suppl 1):115-21.